LENZ Therapeutics (LENZ) to Release Earnings on Wednesday

LENZ Therapeutics (NASDAQ:LENZ - Get Free Report) is expected to issue its quarterly earnings data before the market opens on Wednesday, February 5th. Analysts expect the company to announce earnings of ($0.41) per share for the quarter.

LENZ Therapeutics (NASDAQ:LENZ - Get Free Report) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.47) by $0.09. During the same quarter in the prior year, the company posted ($1.33) EPS. On average, analysts expect LENZ Therapeutics to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

LENZ Therapeutics Trading Up 0.2 %

LENZ traded up $0.05 during trading on Friday, hitting $25.53. The company had a trading volume of 137,432 shares, compared to its average volume of 166,152. The firm's 50-day moving average price is $29.49 and its 200 day moving average price is $26.74. LENZ Therapeutics has a one year low of $14.42 and a one year high of $38.93.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a "buy" rating and set a $38.00 price objective on shares of LENZ Therapeutics in a research report on Thursday, November 7th. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, LENZ Therapeutics presently has a consensus rating of "Buy" and an average price target of $35.40.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.